Clinical Trial Update: Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction [Phase 2]

View source ↗

Summary

A Phase 2 trial tested arsenic trioxide in advanced esophageal and gastroesophageal junction cancers. The study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Esophagus
• Esophageal Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Esophagus, Stage III Esophageal Cancer | Phase 2 | Status: TERMINATED